https://www.runcheyresearch.com/news/rvmd-2026-04-offering Runchey Research en 2026-04-19T21:00:00Z RVMD Raises $2.2B in Upsized Dual-Tranche Offering: Funding Fragility De-Escalates Ahead of Pivotal Readout Filing Analysis, RVMD, Revolution Medicines, Capital Raise, Convertible Notes, Oncology Biotech https://www.runcheyresearch.com/news/ibrx-q1-2026-earnings Runchey Research en 2026-04-19T18:30:00Z IBRX Q1 2026 Preliminary: Cash Crisis Eases, Governance Risk Materializes Earnings Analysis, IBRX, ImmunityBio, Biotech, FDA https://www.runcheyresearch.com/news/lcid-q1-2026-earnings-and-offering Runchey Research en 2026-04-19T19:30:00Z LCID Q1 2026: 29-Day Gravity Disruption + $1.05B Raise + Permanent CEO — March Thesis Mechanisms Validated Earnings Analysis, LCID, Lucid Group, Electric Vehicles, Capital Raise